Condition
Suggested Conditions
- Anxiety
- Depression
- Alzheimer's Disease
- Weight Loss
- Heart Disease
- Cancer
- Asthma
Location
Search Clinical Trials
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
45 Anemia Trials near San Francisco, CA
Power is an online platform that helps thousands of Anemia patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
Learn More About PowerIbrutinib + Rituximab for Chronic Lymphocytic Leukemia
San Francisco, California
This phase III trial studies ibrutinib and rituximab to see how well they work compared to fludarabine phosphate, cyclophosphamide, and rituximab in treating patients with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as fludarabine phosphate and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. It is not yet known whether fludarabine phosphate, cyclophosphamide, and rituximab may work better than ibrutinib and rituximab in treating patients with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Congestive Heart Failure, Hepatitis B, Others
Must Not Be Taking:CYP3A Inhibitors, Warfarin
529 Participants Needed
IST + BMT for Aplastic Anemia
San Francisco, California
Severe Aplastic Anemia (SAA) is a rare condition in which the body stops producing enough new blood cells. SAA can be cured with immune suppressive therapy or a bone marrow transplant. Regular treatment for patients with aplastic anemia who have a matched sibling (brother or sister), or family donor is a bone marrow transplant. Patients without a matched family donor normally are treated with immune suppressive therapy (IST). Match unrelated donor (URD) bone marrow transplant (BMT) is used as a secondary treatment in patients who did not get better with IST, had their disease come back, or a new worse disease replaced it (like leukemia).
This trial will compare time from randomization to failure of treatment or death from any cause of IST versus URD BMT when used as initial therapy to treat SAA.
The trial will also assess whether health-related quality of life and early markers of fertility differ between those randomized to URD BMT or IST, as well as assess the presence of marrow failure-related genes and presence of gene mutations associated with MDS or leukemia and the change in gene signatures after treatment in both study arms.
This study treatment does not include any investigational drugs. The medicines and procedures in this study are standard for treatment of SAA.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:0 - 25
Key Eligibility Criteria
Disqualifiers:Inherited Bone Marrow Syndromes, MDS, HIV, Others
Must Not Be Taking:Androgens, Eltrombopag, Romiplostim, Others
53 Participants Needed
Treosulfan-Based Conditioning for Bone Marrow Failure
San Francisco, California
This trial tests if a combination of three drugs can reduce complications for patients with bone marrow failure diseases. The drugs work by killing harmful cells, stopping their growth, and reducing immune reactions.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:1 - 49
Key Eligibility Criteria
Disqualifiers:Aplastic Anemia, Fanconi Anemia, MDS, Others
40 Participants Needed
In Utero Stem Cell Transplant for Thalassemia
San Francisco, California
The investigators aims to evaluate the safety of in utero hematopoietic stem cell transplantation in fetuses with alpha-thalassemia major performed at the time of in utero transfusion of red blood cells.
No Placebo Group
Trial Details
Trial Status:Enrolling By Invitation
Age:18 - 26
Key Eligibility Criteria
Disqualifiers:Not Listed
10 Participants Needed
Azacitidine +/− Lenalidomide/Vorinostat for Higher-Risk MDS/CMML
San Francisco, California
This randomized phase II/III trial studies how well azacitidine works with or without lenalidomide or vorinostat in treating patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia. Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, stopping them from dividing, or by stopping them from spreading. Lenalidomide may stop the growth of cancer cells by stopping blood flow to the cancer. Vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. It is not yet known whether azacitidine is more effective with or without lenalidomide or vorinostat in treating myelodysplastic syndromes or chronic myelomonocytic leukemia.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:AML, Radiation, Transplant, Neurotoxicity, Others
Must Not Be Taking:Lenalidomide, Azacitidine, Vorinostat, Decitabine
282 Participants Needed
Arginine Therapy for Sickle Cell Disease
San Francisco, California
The trial of IV arginine therapy in children with Vaso-occlusive painful episodes (VOE) in sickle cell disease (SCD) is designed to further knowledge on efficacy and safety of the therapy.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Age:3 - 21
Key Eligibility Criteria
Disqualifiers:Not Listed
360 Participants Needed
Olaparib for Metastatic Breast Cancer
San Francisco, California
This research study is for patients with metastatic breast cancer.
* Metastatic means that the cancer has spread beyond the breast. In addition, through genetic testing of the blood or tumor, an altered gene has been found that suggests the tumor may not be able to repair its genetic material (DNA) when it becomes damaged.
* This aspect of the cancer may cause it to be more sensitive - that is, more effectively killed by certain types of drugs such as the study agent being evaluated in this trial, Olaparib.
* Olaparib is a type of drug known as a PARP inhibitor. Some types of breast cancer and ovarian cancer share some basic features that make them sensitive to similar treatments. Information from those other research studies suggests that this drug may help to treat metastatic breast cancer.
* This study will evaluate whether olaparib is effective in breast cancer patients whose tumor has a mutation in one of the other genes that function with BRCA1 and BRCA2 to repair damaged DNA .This mutation may have been inherited from a parent, or may have developed only in the tumor.
* This study will also evaluate whether olaparib is effective in breast cancer patients whose tumor has a mutation in BRCA1 or BRCA2 that was acquired by the tumor, but not inherited.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:BRCA1/2 Mutation, Brain Metastases, MDS/AML, Others
Must Not Be Taking:PARP Inhibitors, CYP3A Inhibitors
114 Participants Needed
BMS-986470 for Sickle Cell Disease
Oakland, California
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics, pH and food effect, and preliminary efficacy of BMS-986470 in healthy volunteers and participants with sickle cell disease.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Severe VOCs, Acute Chest Syndrome, Others
Must Be Taking:Hydroxyurea
184 Participants Needed
Etavopivat for Sickle Cell Disease
Oakland, California
This trial is testing a drug called etavopivat to see if it can help people with sickle cell disease. The drug aims to improve blood health and reduce pain by making red blood cells work better. The study includes patients aged 12 to 65.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:12 - 65
Key Eligibility Criteria
Disqualifiers:HIV, Hepatitis B/C, Renal Dysfunction, Others
Must Not Be Taking:Voxelotor, Erythropoietin, CYP3A4/5 Inducers
450 Participants Needed
Red Blood Cell Exchange for Sickle Cell Disease
Oakland, California
The SCD-CARRE trial is a Phase 3, prospective, randomized, multicenter, controlled, parallel two-arm study aimed to determine if automated exchange blood transfusion and standard of care administered to high mortality risk adult SCD patients reduces the total number of episodes of clinical worsening of SCD requiring acute health care encounters (non-elective infusion center/ER/hospital visits) or resulting in death over 12 months as compared with standard of care.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:RBC Alloimmunization, Hyper-hemolysis, Severe Transfusion Reaction, Others
173 Participants Needed
Etavopivat for Sickle Cell Anemia
Oakland, California
Etavopivat is a new medicine under development for treating blood disorders like sickle cell disease and thalassaemia. Sickle cell disease and thalassaemia are inherited blood disorders that affect haemoglobin. Haemoglobin is the protein that carries oxygen through the body. This study is looking into how safe treatment with etavopivat is and how well it works over a long period of time. The study will last for up to 264 weeks, but it will end earlier if etavopivat is approved in the participant's country.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:2+
Key Eligibility Criteria
Disqualifiers:Other Disorders, Treatment Withdrawal, Others
Must Be Taking:Hydroxyurea, Crizanlizumab, Endari
480 Participants Needed
Inclacumab for Sickle Cell Disease
Oakland, California
This trial aims to check if extended use of inclacumab, a medication given through an infusion, is safe for people with sickle cell disease who have already used it. The medication is given every few months to help manage the disease.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:12+
Key Eligibility Criteria
Disqualifiers:Pregnancy, Breastfeeding, IRR, Others
Must Be Taking:Inclacumab
147 Participants Needed
Mitapivat for Sickle Cell Disease
Oakland, California
This clinical trial is a Phase 2/3 study that will determine the recommended dose of mitapivat and evaluate the efficacy and safety of mitapivat in sickle cell disease by testing how well mitapivat works compared to placebo to increase the amount of hemoglobin in the blood and to reduce or prevent the occurrence of sickle cell pain crises. In addition, the long-term effect of mitapivat on efficacy and safety will be explored in an open-label extension portion.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2, 3
Age:16+
Key Eligibility Criteria
Disqualifiers:Pregnant, Transfusions, Liver, Kidney, Others
Must Be Taking:Hydroxyurea
286 Participants Needed
Zinc Supplementation for Sickle Cell Disease
Oakland, California
The goal of this short term prospective Phase II study is to compare the effects of two alternate daily doses of zinc (25 and 40 mg/day) in 34 randomly assigned homozygous Sickle Cell Disease (SCD-SS) patients aged 15-40 years old. The main question it aims to answer is: Which biomarkers are most responsive to zinc supplementation, and what is the maximum tolerated zinc dose that induces the desired changes in biomarkers of bone turnover? Participants will be recruited from 6 American Society Hematology Research Collaborative SCD Centers. Eligible SCD subjects will be invited to participate in the 16-week study, involving 2 baseline blood draws 4 weeks apart, followed by a 12-week zinc intervention. The findings from this study will be used to determine the dosage of zinc to be used in a larger, future study on the long term impact of zinc supplementation on bone health in SCD-SS.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:15 - 40
Key Eligibility Criteria
Disqualifiers:Chronic Transfusions, Kidney Disease, Others
Must Not Be Taking:Zinc Supplements
34 Participants Needed
Gene Therapy for Sickle Cell Disease
Oakland, California
This trial uses gene therapy to treat patients with severe Sickle Cell Disease by modifying their own blood stem cells. The treatment aims to increase healthy hemoglobin levels by changing a specific gene. This approach could reduce painful episodes and improve overall health without needing a donor.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:13 - 40
Key Eligibility Criteria
Disqualifiers:Active Infection, Malignancy, Stroke, Others
Must Not Be Taking:Hydroxyurea
25 Participants Needed
Gene Editing (CRISPR) for Sickle Cell Disease
Oakland, California
This trial is testing a one-time treatment for patients with severe Sickle Cell Disease. The treatment aims to correct the genetic defect causing their disease, allowing their bodies to produce healthy red blood cells. The study will initially focus on ensuring the treatment is safe in older patients before expanding to younger ones.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:12 - 35
Key Eligibility Criteria
Disqualifiers:HIV, Hepatitis B/C, Organ Transplant, Others
9 Participants Needed
Stem Cell Transplant for Sickle Cell Disease
Oakland, California
This is an open label, multicenter, Phase 1/2 study in approximately eight adults with severe Sickle Cell Disease (SCD). The study will evaluate the safety, tolerability, and efficacy of autologous hematopoietic stem cell transplantation using BIVV003.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:18 - 40
Key Eligibility Criteria
Disqualifiers:Organ Dysfunction, Active Malignancy, HIV, Others
Must Not Be Taking:Prohibited Medications
8 Participants Needed
NDec for Sickle Cell Disease
Oakland, California
This trial tests a new medicine called NDec for people with sickle cell disease. NDec combines two drugs to help manage the disease. Participants will take capsules regularly over several months to see how well the medicine works and if it is safe.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Chronic Transfusion Therapy, Others
Must Be Taking:Hydroxyurea
84 Participants Needed
Stem Cell Transplant for Sickle Cell Disease
Oakland, California
This study is being done to determine the safety and outcome (long-term control) of a high-dose chemotherapy regimen followed by an infusion of CD34 selected (immune cells) stem cells from a partially matched adult family member donor, called haploidentical stem cell transplantation, in high-risk sickle cell disease patients.
Funding Source - FDA OOPD
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:2 - 20
Key Eligibility Criteria
Disqualifiers:Pregnancy, Uncontrolled Infection, Fibrosis, Others
21 Participants Needed
EDIT-301 for Sickle Cell Disease
Oakland, California
This trial is testing a new treatment called EDIT-301 for people aged 12 to 50 with severe sickle cell disease. The treatment uses the patient's own stem cells, which are changed in a lab and then put back into their body to help fight the disease.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:12 - 50
Key Eligibility Criteria
Disqualifiers:HLA-matched Donor, Prior HSCT, Vasculopathy, Malignancy, Others
Must Not Be Taking:Hydroxyurea, Voxelotor, Crizanlizumab, L-glutamine
45 Participants Needed
Why Other Patients Applied
"My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."
HZ
Arthritis PatientAge: 78
"I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."
WR
Obesity PatientAge: 58
"I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."
AG
Paralysis PatientAge: 50
"I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."
ZS
Depression PatientAge: 51
"As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."
IZ
Healthy Volunteer PatientAge: 38
Luspatercept vs Epoetin Alfa for MDS-related Anemia
Berkeley, California
The purpose of this study is to determine the effectiveness of luspatercept (ACE-536) compared to epoetin alfa on red blood cell (RBC) transfusion independence (for at least 12 weeks) with a concurrent hemoglobin increase of at least 1.5 g/dL in participants with anemia due to revised international prognostic scoring system (IPSS-R) very low, low, or intermediate risk myelodysplastic syndromes (MDS) who require RBC transfusions and have never been exposed to erythropoiesis stimulating agent (ESA).
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Iron Deficiency, B12 Deficiency, Folate Deficiency, Autoimmune Anemia, AML, Others
363 Participants Needed
Benserazide for Beta Thalassemia
Oakland, California
Beta-thalassemias and hemoglobinopathies are serious inherited blood diseases caused by abnormal or deficiency of beta A chains of hemoglobin, the protein in red blood cells which delivers oxygen throughout the body.The diseases are characterized by hemolytic anemia, organ damage, and early mortality without treatment. Increases in another type of (normal) hemoglobin, fetal globin (HbF), which is normally silenced in infancy, reduces anemia and morbidity. Even incremental augmentation of fetal globin is established to reduce red blood cell pathology, anemia, certain complications, and to improve survival.
This trial will evaluate an oral drug discovered in a high throughput screen, which increases fetal globin protein (HbF and red blood cells expressing HbF)and messenger ribonucleic acid (mRNA) to high levels in anemic nonhuman primates and in transgenic mice. The study drug acts by suppressing 4 repressors of the fetal globin gene promoter in progenitor cells from patients. The drug has been used for 50 years in a combination product for different actions - to enhance half-life and reduce side effects of a different active drug- and is considered safe for long-term use.
This trial will first evaluate 3 dose levels in small cohorts of nontransfused patients with beta thalassemia intermedia. The most active dose will then be evaluated in larger subject groups with beta thalassemia and other hemoglobinopathies, such as sickle cell disease.
No Placebo Group
Trial Details
Trial Status:Enrolling By Invitation
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:RBC Transfusion, Pulmonary Hypertension, Others
Must Not Be Taking:Erythropoiesis Agents, MAO Inhibitors
36 Participants Needed
Etavopivat for Sickle Cell Disease
Oakland, California
This trial is testing a new oral medicine called etavopivat in patients with sickle cell disease or thalassemia. The medicine helps red blood cells produce energy more efficiently. The goal is to reduce the need for blood transfusions and increase hemoglobin levels.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:12 - 65
Key Eligibility Criteria
Disqualifiers:Hepatic Dysfunction, HIV, Hepatitis B/C, Others
60 Participants Needed
Lenalidomide +/− Epoetin Alfa for Myelodysplastic Syndrome
Greenbrae, California
This randomized phase III trial studies lenalidomide to see how well it works with or without epoetin alfa in treating patients with myelodysplastic syndrome and anemia. Lenalidomide may stop the growth of myelodysplastic syndrome by blocking blood flow to the cells. Colony stimulating factors, such as epoetin alfa, may increase the number of immune cells found in bone marrow or peripheral blood. It is not yet known whether lenalidomide is more effective with or without epoetin alfa in treating patients with myelodysplastic syndrome and anemia.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Pregnancy, Uncontrolled Hypertension, HIV, Others
Must Be Taking:Lenalidomide
247 Participants Needed
Etavopivat for Sickle Cell Disease
Redwood City, California
This study is conducted to confirm whether etavopivat works well at reducing the number of Vaso-occlusive crisis VOCs (sickle cell pain crises) caused by obstructions in blood vessels in adults and adolescents living with sickle cell disease. The study will also evaluate how well etavopivat can reduce the damage to different organs, improve your exercise tolerance and reduce fatigue in people with sickle cell disease.The participants will either get etavopivat or placebo. Which treatment the participants will get is decided by chance. Etavopivat is a new medicine and is currently being tested in other studies in addition to this one. The study will last for about 2 years.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:12+
Key Eligibility Criteria
Disqualifiers:More Than 15 VOCs, Chronic Transfusion, Hepatic Dysfunction, Severe Renal Dysfunction, Others
Must Be Taking:Antimalarial Prophylaxis
408 Participants Needed
Epoetin Alfa vs Luspatercept for Myelodysplastic Syndrome
Walnut Creek, California
This trial is testing two treatments, Luspatercept and epoetin alfa, to see which is better for treating anemia in adults with certain types of myelodysplastic syndromes (MDS). The participants have not used similar treatments before and do not need regular blood transfusions. Luspatercept helps red blood cells mature, while epoetin alfa increases their production.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Secondary MDS, AML, Stroke, Others
360 Participants Needed
Mitapivat for Pyruvate Kinase Deficiency
Palo Alto, California
This trial is testing an oral medication called mitapivat in children with a genetic condition affecting their red blood cells. The goal is to see if mitapivat can help their red blood cells work better and improve their health without needing frequent blood transfusions.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:1 - 17
Key Eligibility Criteria
Disqualifiers:Pregnancy, Malignancy, Cardiac Disease, Others
Must Be Taking:Folic Acid
30 Participants Needed
Mitapivat for Pyruvate Kinase Deficiency
Palo Alto, California
This trial is testing mitapivat, a medication that may help children with a blood disorder called pyruvate kinase deficiency. These children often need frequent blood transfusions. Mitapivat aims to improve the function of their red blood cells, potentially reducing the need for these transfusions.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:1 - 17
Key Eligibility Criteria
Disqualifiers:Pregnancy, Malignancy, Cardiac Disease, Others
Must Be Taking:Folic Acid
49 Participants Needed
INCB000928 + Ruxolitinib for Myelofibrosis
Palo Alto, California
This trial is testing a new drug called INCB000928, either alone or with ruxolitinib, to see if it is safe and effective. It targets people with Myelofibrosis who need regular blood transfusions or have severe anemia. The goal is to see if the drug can reduce the need for transfusions and improve anemia symptoms.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Stem Cell Transplantation, Others
Must Be Taking:Ruxolitinib
84 Participants Needed
INTERCEPT Treated RBCs for Anemia
Stanford, California
This trial is testing a special type of blood transfusion for patients having complex heart surgery. The new treatment aims to make blood transfusions safer by reducing infections and complications. The study will evaluate if this new method works effectively.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Age:11+
Key Eligibility Criteria
Disqualifiers:Not Listed
292 Participants Needed
Know someone looking for new options?
Spread the word